VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau,Cyrille Hulin,Margaret Macro,Denis Caillot,Carine Chaleteix,Murielle Roussel,Laurent Garderet,Bruno Royer,Sabine Brechignac,Mourad Tiab,Mathieu Puyade,Martine Escoffre,Anne-Marie Stoppa,Thierry Facon,Brigitte Pegourie,Driss Chaoui,Arnaud Jaccard,Borhane Slama,Gerald Marit,Karim Laribi,Pascal Godmer,Odile Luycx,Jean Claude Eisenmann,Olivier Allangba,Mamoun Dib,Carla Araújo,Jean Fontan,Karim Belhadj,Marc Wetterwald,Véronique Dorvaux,Jean-Paul Fermand,Philippe Rodon,Brigitte Kolb,Sylvie Glaisner,Jean-Valère Malfuson,Pascal Lenain,Laetitia Biron,Lucie Planche,Helene Caillon,Hervé Avet-Loiseau,Thomas Dejoie,Michel Attal

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

2016

The Intergroupe Francophone du Myelome conducted a randomized trial to compare bortezomib-thalidomide-dexamethasone (VTD) with bortezomib-cyclophosphamide-dexamethasone (VCD) as induction before high-dose therapy and autologous stem cell transplantation (ASCT) in patients with newly diagnosed

Keywords:

Randomized controlled trial
Bortezomib
Immunology
Autologous stem-cell transplantation
Multiple myeloma
Medicine
Thalidomide
Neutropenia
Prospective cohort study
Clinical endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

158

Citations